• Background
• Hypertension
• Arteriosclerosis, Atherosclerosis
• Congestive Heart Failure
• Scope and Methodology
• Size and Growth of Market
• Competitive Picture
• Market Trends and Factors

Chapter Two: Introduction

• Background
• Population Demographics
• Epidemiology and Pathology of Cardiovascular Diseases
  • Hypertension
  • Arteriosclerosis/Atherosclerosis
  • Congestive Heart Failure
    • Left Ventricular (LV) Failure
    • Right Ventricular (RV) Failure
    • Systolic Dysfunction
    • Diastolic Dysfunction
    • High Output Failure
    
    
  • Theories of Congestive Heart Failure
    • Hemodynamic Response Theory
    • Neurohormonal Response Theory
    • Renal Response Theory
    
    
  • Conditions Leading to Congestive Heart Failure
    • Myocardial Infarction
    • Hypertension
    • Cardiomyopathy
    • Atrial Fibrillation
    • Other Risk Factors

Chapter Three: Cardiovascular Therapeutics

• Hypertension and Antihypertensive Drugs
  • ACE Inhibitors
  • á/â(Alpha/Beta)-Blockers
  • Calcium Channel Blockers
  • Diuretics
  • Angiotensin II Receptor Antagonists
  
  
• Atherosclerosis/Arteriosclerosis Therapy
  • Antilipemic Agents
  • Blood Modifiers
    • Anticoagulants
    • Antiplatelet Agents
    • Antithrombin III
    • Thrombin Inhibitors
    • Thrombolytic Agents
    
    
  • Surgical Stents
  • Clinical, Business, and Regulatory Developments in Drug-Eluting Stents
  • Alternatives to Drug-Eluting Stents
  
  
• Congestive Heart Failure Treatment
  • Left Ventricular (LV) Failure
  • Right Ventricular (RV) Failure
  • Systolic Dysfunction
  • Diastolic Dysfunction
  • High Output Failure
  • Hemodynamic Response Theory
  • Neurohormonal Response Theory
  • Renal Response Theory
  
  
  • ACE Inhibitors and Related Drugs
  • Angiotensin II Receptor Blockers
  • â-Blockers
    • Mild Heart Failure
    • Moderate Heart Failure
    • Severe Heart Failure
    
    
  • Diuretics
  • Positive Inotropic Agents
  • Vasodilators
  • Supplements
  • CHF Devices
    • Bridge to Transplant
    • Extended Use
    • Intervention Device Products
  
  
• Emerging Therapeutic Approaches
  • Pharmacological Approaches
    • Atacand® (candesartan cilexetil, AstraZeneca)
    • Avapro® (irbesartan, Bristol-Myers Squibb)
    • Celacade™ (Vasogen)
    • Citicoline (Indevus)
    • CVT-510 (tecadenoson, Cardiovascular Therapeutics)
    • Enoximone (Myogen)
    • Exanta® (ximelagatran, AstraZeneca)
    • Ezetimibe/Simvastatin Tablet (Merck/Schering-Plough)
    • E2F Decoy (Corgentech)
    • HRC 102 (Hemosol Research Corporation)
    • ReoPro® (abciximab, Centocor/Eli Lilly)
    • Sitaxsentan (Encysive Pharmaceuticals)
    • Vanlev® (omapatrilat, Bristol-Myers Squibb)
    • Veletri™ (tezosentan, Actelion)
    
    
  • Device Approaches

Chapter Four: Market Analysis

• Market Size and Growth
  • Overview: The Total Market Potential
  
  
• The 45+-Year-Old Market: A General View
• Congestive Heart Failure
• Arteriosclerosis
• Cardiovascular Market Potentials by Age Sub-Segment
• Market Potential by Age Sub-Segment within Condition
  • Hypertension
  • Arteriosclerosis
  • Congestive Heart Failure
  
  
• Competitive Outlook
• Market Trends

Chapter Five: Conclusions and Strategic Implications

• First Conclusion
• Second Conclusion
• Third Conclusion
• Fourth Conclusion
• Fifth Conclusion
• Sixth Conclusion
• Seventh Conclusion
• Eighth Conclusion
• Ninth Conclusion

• Overview
• Abbott Laboratories
• Abiomed, Inc.
• Acorn Cardiovascular, Inc.
• Actelion, Ltd.
• Arrow International
• Astra Zeneca
• Aventis Pharma USA Division of Aventis
• Bioheart, Inc.
• Boston Scientific
• Bristol-Myers Squibb
• Cardioenergetics, Inc.
• Cordis Corporation (A Johnson & Johnson Company)
• CV Therapeutics
• Encysive Pharmaceuticals (Formerly Texas Biotechnology Corporation)
• Geron Corporation
• GlaxoSmithKline
• Guidant Corporation
• Medtronic, Inc.
• MicroMed Technology, Inc.
• Myocor, Inc.
• Myogen
• Pfizer, Inc.
• St. Jude Medical
• Somanetics Corporation
• Thoratec Corporation

Appendix: Company Directory

List of Exhibits
Chapter One: Executive Summary

• Table 1-1: Prevalence of Cardiovascular Diseases (CVD) in the United States for the Total Population and Those 45 Years of Age and Older: 2003-2013
• Figure 1-1: Trending in U.S. Cardiovascular Disease Prevalence in the General Population and the 45+ Year Old Age Group: 2003 - 2013
• Figure 1-2: Trending in U.S. Hypertension Cases in the 45+ Year Old Age Groups: 2003-2013
• Figure 1-3: Trending in U.S. Arteriosclerosis Cases in the 45+-Year-Old Age Groups: 2003-2013
• Figure 1-4: Trending in U.S. Congestive Heart Failure (CHF) Cases in the 45+- Year-Old Age Groups: 2003-2013
• Table 1-2: The Total Projected U.S. Total Available Market Potential (TAMP-45+) and Serviceable Available Market (SAMP-45+) for Hypertension, Arteriosclerosis, and Congestive Heart Failure Therapeutics in the 45+-Year-Old Population 2003-2013
• Figure 1-5: Trending in the Total Projected U.S. Total Available Market Potential and Serviceable Available Market Potential for Cardiovascular Therapeutics in the 45+-Year-Old Population 2003-2013

Chapter Two: Introduction

• Figure 2-1: Growth of the World’s Elderly (60+ Years) Population 2001 - 2025
• Figure 2-2: Population Distribution of the United States by Age and Sex for 1999 and 2025
• Figure 2-3: The Growing U.S. Population 2003-2013
• Figure 2-4: Increasing Median Age of the U.S. Population
• Figure 2-5: Increasing Mean Age of the U.S. Population
• Table 2-1: Aging of the U.S. Population in the Age Groups 45 Years and Older 2003-2013
• Figure 2-6: Aging Trends in the U.S. Population for the Age Groups 45 Years and Older 2003-2013
• Figure 2-7: Changes in the Composition of the 45 Year-Old and Older Age Segment in the United States: 2003 and 2013
• Table 2-2: Older Population Groups as Percentages of the Total U.S. Population by Age Group 2003-2013
• Figure 2-8: Aging Trends by Percentage of the U.S. Population for the Age Groups 45 Years and Older: 2003-2013
• Table 2-3: Prevalence of Cardiovascular Diseases (CVD) in the United States for the Total Population and Those 45 Years of Age and Older: 2003-2013
• Figure 2-9: Trending in U.S. Cardiovascular Disease (CVD) Cases in the General Population and the 45+ Year Old Age Group 2003 - 2013
• Table 2-4: Prevalence of Hypertension Cases in the United States for Those 45 Years of Age and Older by Age Groups 2003-2013
• Figure 2-10: Trending in U.S. Hypertension Cases in the 45+-Year-Old Age Groups 2003-2013
• Table 2-5: Prevalence of Arteriosclerosis Cases in the United States for Those 45 Years of Age and Older by Age Groups 2003-2013
• Figure 2-11: Trending in U.S. Arteriosclerosis Cases in the 45+-Year-Old Age Groups 2003-2013
• Table 2-6: Common Contributors to Congestive Heart Failure
• Table 2-7: Prevalence of Congestive Heart Failure (CHD) Cases in the United States for Those 45 Years of Age and Older by Age Groups: 2003-2013
• Figure 2-12: Trending in U.S. Congestive Heart Failure (CHF) Cases in the 45+- Year-Old Age Groups: 2003-2013

Chapter Three: Cardiovascular Therapeutics

• Table 3-1: Common ACE Inhibitors on the Market for Hypertension
• Table 3-2: Common Adrenergic Receptor (á and â) Blockers on the Market for Hypertension
• Table 3-3: Common Calcium Channel Blockers on the Market for Hypertension
• Table 3-4: Common Diuretic Products on the Market for Hypertension
• Table 3-5: Common Combined Diuretic Products on the Market for Hypertension
• Table 3-6: Common Angiotensin II Receptor Antagonists on the Market for Hypertension
• Table 3-7: Commonly Used Anti-Lipemic Agents on the Market for the Treatment of Dyslipidemia
• Table 3-8: Commonly Used Blood Modifying Agents on the Market for the Treatment of Cardiovascular Disease
• Table 3-9: Candidate Compounds for Drug-Eluting Stents
• Table 3-10: Therapeutic Strategies for Symptomatic Congestive Heart Failure
• Table 3-11: Pharmacological Response to the Pathophysiology of Cardiac Performance
• Table 3-12: Common Inotropic Drugs Available for the Treatment of CHF
• Table 3-13: Common Vasodilators Available for the Treatment of CHF
• Table 3-14: Biventricular Pacemakers for CHF Therapy
• Table 3-15: Cardioverter/Defibrillators (ICD) Available for Use in the Treatment of CHF
• Table 3-16: Ventricular Assist Devices (VADs) on the Market and in Development
• Table 3-17: New Drugs in Development for Cardiovascular Conditions
• Table 3-18: Key New Devices in Development for Cardiovascular Therapy

Chapter Four: Market Analysis

• Table 4-1: The Total Projected U.S. Total Available Market Potential (TAMP) and Serviceable Available Market (SAMP) for Hypertension, Arteriosclerosis and Congestive Heart Failure Therapeutics 2003-2013
• Figure 4-1: Trending in the Total Projected U.S. Total Available Market Potential (TAMP) and Serviceable Available Market Potential (SAMP) for Hypertension, Arteriosclerosis and Congestive Heart Failure Therapeutics 2003-2013
• Figure 4-2: Trending in the Total Projected U.S. Total Available Market Potential (TAMP) and Serviceable Available Market Potential (SAMP) For the Treatment of Hypertension 2003-2013
• Figure 4-3: Trending in the Total Projected U.S. Total Available Market Potential (TAMP) and Serviceable Available Market Potential (SAMP) for the Treatment of Congestive Heart Failure 2003-2013
• Figure 4-4: Trending in the Total Projected U.S. Total Available Market Potential (TAMP) and Serviceable Available Market Potential (SAMP) for the Treatment of Arteriosclerosis 2003-2013
• Table 4-2: The Total Projected U.S. Total Available Market Potential (TAMP-45+) and Serviceable Available Market (SAMP-45+) for Hypertension, Arteriosclerosis and Congestive Heart Failure Therapeutics in the 45+-Year-Old Population 2003-2013
• Figure 4-5: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-45+) and Serviceable Available Market Potential (SAMP-45+) for Hypertension, Arteriosclerosis and Congestive Heart Failure Therapeutics in the 45+-Year-Old Population 2003-2013
• Table 4-3: The Total Projected U.S. Total Available Market Potential (TAMP-45+) and Serviceable Available Market (SAMP-45+) for Congestive Heart Failure Therapeutics in the 45+-Year-Old Population 2003-2013
• Figure 4-6: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-45+) and Serviceable Available Market Potential (SAMP-45+) Congestive Heart Failure Therapeutics in the 45+-Year-Old Population 2003-2013
• Figure 4-7: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-45+) and Serviceable Available Market Potential (SAMP-45+) Congestive Heart Failure Drugs in the 45+-Year-Old Population 2003-2013
• Figure 4-8: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-45+) and Serviceable Available Market Potential (SAMP-45+) Congestive Heart Failure Devices in the 45+-Year-Old Population 2003-2013
• Table 4-4: The Total Projected U.S. Total Available Market Potential (TAMP-45+) and Serviceable Available Market (SAMP-45+) for Arteriosclerosis Therapeutics in the 45+-Year-Old Population: 2003-2013
• Figure 4-9: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-45+) and Serviceable Available Market Potential (SAMP-45+) for Arteriosclerosis Therapeutics in the 45+-Year-Old Population: 2003-2013
• Figure 4-10: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-45+) and Serviceable Available Market Potential (SAMP-45+) Antihyperlipemic Drugs in the 45+-Year-Old Population: 2003-2013
• Figure 4-11: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-45+) and Serviceable Available Market Potential (SAMP-45+) Drug-Eluting Stents in the 45+-Year-Old Population: 2003-2013
• Figure 4-12: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-45+) and Serviceable Available Market Potential (SAMP-45+) Blood Modifying Drugs in the 45+-Year-Old Population: 2003-2013
• Figure 4-13: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-45+) and Serviceable Available Market Potential (SAMP-45+) Antihypertensive Drugs in the 45+-Year-Old Population: 2003-2013
• Table 4-5: The Total Projected U.S. Total Available Market Potential (TAMP-45+) and Serviceable Available Market (SAMP-45+) for Cardiovascular Disease Therapeutics by Age Group in the 45+-Year-Old Population 2003-2013
• Figure 4-14: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-45/54) and Serviceable Available Market (SAMP-45/54) for Cardiovascular Disease Therapeutics by Application in the 45-to- 54-Year-Old Population 2003-2013
• Figure 4-15: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-55/64) and Serviceable Available Market (SAMP-55/64) for Cardiovascular Disease Therapeutics by Application in the 55-to- 64-Year-Old Population 2003-2013
• Figure 4-16: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-65/74) and Serviceable Available Market (SAMP-65/74) for Cardiovascular Disease Therapeutics by Application in the 65-to- 74-Year-Old Population: 2003-2013
• Figure 4-17: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-75+) and Serviceable Available Market (SAMP-75+) for Cardiovascular Disease Therapeutics by Application in the 75+- Year-Old Population: 2003-2013
• Table 4-6: The Total Projected U.S. Total Available Market Potential (TAMP-45+) and Serviceable Available Market (SAMP-45+) for Antihypertensive Drugs by Age Group in the 45+-Year-Old Population 2003-2013
• Figure 4-18: Trending in the Total Projected U.S. Total Available Market P otential (TAMP-45/54) and Serviceable Available Market (SAMP-45/54) for Antihypertensive Drugs in the 45-to-54-Year-Old Population 2003-2013
• Figure 4-19: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-55/64) and Serviceable Available Market (SAMP-55/64) for Antihypertensive Drugs in the 55-to-64-Year-Old Population 2003-2013
• Figure 4-20: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-65/74) and Serviceable Available Market (SAMP-65/74) for Antihypertensive Drugs in the 65-to-74-Year-Old Population 2003-2013
• Figure 4-21: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-75+) and Serviceable Available Market (SAMP-75+) for Antihypertensive Drugs in the 75+-Year-Old Population 2003-2013
• Table 4-7: The Total Projected U.S. Total Available Market Potential (TAMP-45+) and Serviceable Available Market (SAMP-45+) for Arteriosclerosis Therapeutics by Age Group in the 45+-Year-Old Population 2003-2013
• Figure 4-22: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-45/54) and Serviceable Available Market (SAMP-45/54) for Arteriosclerosis Therapeutics in the 45-to-54-Year-Old Population 2003-2013
• Figure 4-23: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-55/64) and Serviceable Available Market (SAMP-55/64) for Arteriosclerosis Therapeutics in the 55-to-64-Year-Old Population 2003-2013
• Figure 4-24: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-65/74) and Serviceable Available Market (SAMP-65/74) for Arteriosclerosis Therapeutics in the 65-to-74-Year-Old Population 2003-2013
• Figure 4-25: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-75+) and Serviceable Available Market (SAMP-75+) for Arteriosclerosis Therapeutics in the 75+-Year-Old Population 2003-2013
• Table 4-8: The Total Projected U.S. Total Available Market Potential (TAMP-45+) and Serviceable Available Market (SAMP-45+) for Congestive Heart Failure by Age Group in the 45+-Year-Old Population: 2003-2013
• Figure 4-26: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-45/54) and Serviceable Available Market (SAMP-45/54) for Congestive Heart Failure in the 45-to-54-Year-Old Population 2003-2013
• Figure 4-27: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-55/64) and Serviceable Available Market (SAMP-55/64) for Congestive Heart Failure in the 55-to-64-Year-Old Population 2003-2013
• Figure 4-28: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-65/74) and Serviceable Available Market (SAMP-65/74) for Congestive Heart Failure in the 65-to-74-Year-Old Population 2003-2013
• Figure 4-29: Trending in the Total Projected U.S. Total Available Market Potential (TAMP-75+) and Serviceable Available Market (SAMP-75+) for Congestive Heart Failure in the 75+-Year-Old Population 2003-2013